Share This Link

Norethindrone and ethinyl estradiol, which are combined oral contraceptives (COCs), do not destroy a fertilized egg. They work primarily to prevent fertilization, not to terminate an established pregnancy. This statement could mislead patients and is not physiologically accurate.

COCs actually suppress the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary, preventing ovulation. They do not increase hormone production; in fact, the suppression of FSH and LH prevents the ovarian follicle from maturing and releasing an egg.

The contraceptive effect of COCs prevents follicle maturation and ovulation rather than inducing it. Promoting follicular development would actually increase the likelihood of pregnancy.

Amantadine is an antiviral agent with dopaminergic activity used in early Parkinson’s disease to reduce symptoms such as tremor and rigidity. It is generally well-tolerated and does not have significant effects on peripheral blood vessels, so caution in peripheral vascular disease (PVD) is not specifically required.

Rasagline is a monoamine oxidase-B (MAO-B) inhibitor that prevents the breakdown of dopamine, helping to manage Parkinson’s symptoms. It does not have vasoconstrictive properties and is not specifically contraindicated or used cautiously in patients with PVD.

Ropinirole is a dopamine agonist that can cause hypotension, especially orthostatic hypotension, but it does not typically exacerbate peripheral vascular disease. It requires monitoring in patients prone to blood pressure changes, but caution for PVD specifically is not a primary concern.

Phenytoin should never be given as a rapid IV push because this can cause severe cardiovascular complications, including hypotension and arrhythmias. IV administration must always be slow and controlled, not as a rapid push.

Phenytoin is typically given on a scheduled basis to maintain therapeutic blood levels and prevent seizures, not PRN. The order every eight hours is consistent with standard scheduled therapy.

While long-term phenytoin therapy is associated with adverse effects such as gingival hyperplasia and hirsutism, this is not a reason to question the rate or frequency of IV administration. These side effects are related to chronic use, not immediate IV dosing.

Constipation is not a common or expected adverse effect of beta interferon therapy. While patients may experience gastrointestinal changes, constipation is not a hallmark side effect.

Weight gain is not a typical adverse effect of beta interferon. In fact, some patients may experience weight loss due to other side effects such as appetite changes or flu-like symptoms.

Anorexia or decreased appetite is not a common adverse effect. While mild gastrointestinal upset can occur in some patients, it is not the primary reaction nurses should emphasize during patient education.

Tocolytics are medications that suppress uterine contractions, not stimulate them. Stimulating contractions is actually the opposite of their intended effect and could worsen preterm labor. Examples of medications that stimulate contractions include oxytocin or prostaglandins, which are used for labor induction, not tocolysis. Choosing this answer would indicate a misunderstanding of the mechanism of action of tocolytic therapy.

Tocolytics are not abortifacients and are not intended to terminate a pregnancy. Their purpose is to maintain pregnancy for as long as safely possible. Confusing tocolytics with medications that induce abortion, such as mifepristone or misoprostol, shows a fundamental misunderstanding of their clinical use.

While tocolytics have potential side effects for both mother and fetus, including maternal tachycardia, hypotension, or fluid retention, their primary function is not to harm the fetus. In fact, they are administered with careful monitoring to protect fetal development by delaying preterm birth. A student stating that tocolytics cause fetal harm demonstrates an inaccurate perception of their risk-benefit profile and purpose in clinical care.

Bromocriptine is a dopamine agonist used to treat conditions like Parkinson’s disease and hyperprolactinemia. It does not carry a black box warning for tuberculosis or serious infections. Choosing this answer would reflect a misunderstanding of the drug’s indications and safety profile.

Belimumab is a monoclonal antibody used to treat systemic lupus erythematosus (SLE). While it carries warnings for serious infections, it is not specifically associated with fatal tuberculosis. Therefore, this is not the correct choice for a patient with Crohn’s disease at risk for TB.

Ropinirole is another dopamine agonist used primarily for Parkinson’s disease and restless leg syndrome. It does not carry a black box warning for TB or severe infections and is unrelated to Crohn’s disease management.

RhoGAM does not protect against rubella, which is a viral infection. Rubella vaccination is handled separately, typically before pregnancy or postpartum if the client is non-immune. Confusing these two interventions reflects a misunderstanding of prenatal preventive care.

The fetus does not "develop Rh+ blood" as a result of maternal Rh status. Rh status is genetically determined. RhoGAM does not change the fetal blood type; it prevents maternal sensitization to fetal Rh-positive red blood cells.

Pernicious anemia is caused by vitamin B12 deficiency and has no connection to Rh incompatibility or RhoGAM administration. Selecting this option would demonstrate a misunderstanding of the indication for RhoGAM.

Serum albumin measures nutritional status and liver function but is not a primary indicator of azathioprine toxicity or effectiveness. Monitoring albumin alone does not provide information about the patient’s immune suppression or risk for infection.

Serum calcium levels are not significantly affected by azathioprine. Monitoring calcium is more relevant for patients on medications like loop diuretics or corticosteroids or those with bone metabolism disorders, not for routine azathioprine therapy.

Serum potassium is primarily monitored in patients taking ACE inhibitors, potassium-sparing diuretics, or other medications that alter renal potassium excretion. Azathioprine does not typically impact potassium levels.

Osteoporosis is actually an indication for estrogen therapy, not a contraindication. Estrogens help maintain bone density by reducing bone resorption after menopause, which decreases the risk of fractures. Patients with osteoporosis may benefit from estrogen therapy under careful monitoring, making this an inappropriate reason to withhold the medication.

Atrophic vaginitis results from decreased estrogen levels, leading to vaginal dryness, irritation, and discomfort. Estrogen therapy, including conjugated equine estrogens, can improve vaginal tissue health, restore normal mucosa, and reduce symptoms. Therefore, a history of atrophic vaginitis is not a contraindication but may actually support the therapeutic use of estrogen.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal pain, bloating, and changes in bowel habits. Estrogen therapy has no direct impact on IBS, and IBS is not listed as a contraindication for systemic estrogen use. Selecting this option indicates a misunderstanding of the relevant safety considerations.